Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors

Justin A. Chen, Jonathan W. Riess

Research output: Contribution to journalReview article

Abstract

Next-generation sequencing (NGS) of tumor samples and circulating tumor DNA has revolutionized diagnostic and therapeutic strategies in lung cancer. The identification of the epidermal growth factor receptor (EGFR) oncogenic driver has translated into successful therapy of advanced lung cancer using EGFR tyrosine kinase inhibitors (TKI). Unfortunately, responses are limited by acquired mechanisms of resistance. We review herein the current landscape of acquired resistance mechanisms to EGFR-TKI therapy and recent advances in therapeutic strategies to overcome acquired resistance.

Original languageEnglish (US)
Pages (from-to)2859-2876
Number of pages18
JournalJournal of Thoracic Disease
Volume12
Issue number5
DOIs
StatePublished - May 1 2020

Keywords

  • Carcinoma
  • Drug resistance
  • Epidermal growth factor
  • Lung neoplasms
  • Non-small cell lung
  • Protein kinase inhibitors
  • Receptor

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors'. Together they form a unique fingerprint.

  • Cite this